Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Delayed Second Dose of Oral Cholera Vaccine
NCT05453253Phase 4Unknown
- Sponsor
- Illumina
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Killed bivalent (O1 and O139) whole cell oral cholera vaccine in cholera (3 arms), sponsored by Illumina. Primary endpoint: Serum vibriocidal antibody specific to V. cholerae O1, Inaba, Ogawa and O139 strains. Status: unknown.
02
Drugs
Killed bivalent (O1 and O139) whole cell oral cholera vaccine
03
Conditions
cholera
Beyond the preview
Go deeper on NCT05453253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453253.